• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Thursday, January 21, 2021
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Science

Researchers identify new drug target for gastrointestinal stromal tumors

Bioengineer by Bioengineer
November 1, 2016
in Science
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram
IMAGE

Credit: UC San Diego Health

Researchers at University of California San Diego School of Medicine and Mayo Clinic provide the first evidence that the Hedgehog signaling pathway is central to the formation of gastrointestinal stromal tumors (GIST), which are frequently driven by the KIT oncogene. Results of the human study were recently published online in Oncotarget.

"Our new finding is a step forward in overcoming tyrosine kinase inhibitor resistance, a clinically significant problem in the management of GIST," said Jason Sicklick, MD, associate professor of surgery at UC San Diego School of Medicine and surgical oncologist at Moores Cancer Center at UC San Diego Health. "By knowing that Hedgehog signaling is altered in human GIST, and that it controls KIT expression, we may have found a way to turn the cancer off."

GISTs eventually become highly resistant to current drug therapies. Clinicians fight the growth with progressively aggressive drugs, the downside being that each later line of therapy has diminishing effectiveness and higher toxicity for patients. More than 95 percent of patients eventually succumb to drug-resistant GIST, necessitating the search for alternative therapeutic targets.

"We may have found this cancer's 'on' switch," said Sicklick. "We are flipping the switch 'off' with arsenic, a drug that is already in clinical practice. With this drug, we are able to kill multidrug-resistant cell lines, offering a new approach to treatment."

GIST is the most common sarcoma with an estimated annual incidence of 6.8 cases per million people in the United States. These tumors start in special cells found in the wall of the GI tract, called the interstitial cells of Cajal (ICCs). ICCs are sometimes called the "pacemakers" of the GI tract because they signal the muscles in the digestive system to contract to move food and liquid through the GI tract.

Sicklick was recently named by The Life Raft Group, a national advocacy group that supports research and treatment of GIST, as their Clinician-of-the-Year for 2016. As a physician-scientist, Sicklick is dedicated to understanding GIST at the basic science level while finding treatments for GIST that are best for adult, adolescent and pediatric patients. Tamas Ordog, MD, co-senior author of the paper, is a basic scientist known for his research on ICCs. He is affiliated with the Mayo Clinic Center for Individualized Medicine and he is a member of the Life Raft Group Research Team.

###

Moores Cancer Center is the region's only NCI-designated comprehensive cancer center. It is also the first and only San Diego-based member of the National Comprehensive Cancer Network, an alliance of the world's leading cancer centers. Moores Cancer Center currently operates more than 170 open treatment trials. These investigational therapies include advanced, highly personalized stem cell-based approaches and immunotherapies that leverage the inherent healing powers of the human body.

To learn more about the treatment of GIST at Moores Cancer Center, visit: https://health.ucsd.edu/specialties/cancer/programs/gastrointestinal/Pages/gist.aspx

Contributors to this paper include: Chih-Min Tang, Tracy E. Lee, Adam M. Burgoyne, Stephanie Y. Leonard, Jonathan C. Chan, Eileen Shi, Martina De Siena, and Olivier Harismendy from UC San Diego; Sabriya A. Syed, Fei Gao, Michael L. Kendrick, and Michael R. Bardsley from Mayo Clinic; Junhao Mao from University of Massachusetts, Worchester, Massachusetts; and Juliann Chmielecki, Deborah Morosini, Kai Wang, and Jeffrey S. Ross from Foundation Medicine Inc.

Media Contact

Jackie Carr
[email protected]
858-249-0456
@UCSanDiego

http://www.ucsd.edu

Share13Tweet7Share2ShareShareShare1

Related Posts

Five or more hours of smartphone usage per day may increase obesity

July 25, 2019
IMAGE

NASA’s terra satellite finds tropical storm 07W’s strength on the side

July 25, 2019

NASA finds one burst of energy in weakening Depression Dalila

July 25, 2019

Researcher’s innovative flood mapping helps water and emergency management officials

July 25, 2019
Next Post

New drug combination has potential to significantly improve chemotherapy success

blank

Database captures most extensive urban tree sizes, growth rates across United States

Leave a Reply Cancel reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

POPULAR NEWS

  • IMAGE

    The map of nuclear deformation takes the form of a mountain landscape

    54 shares
    Share 22 Tweet 14
  • People living with HIV face premature heart disease and barriers to care

    63 shares
    Share 25 Tweet 16
  • New drug form may help treat osteoporosis, calcium-related disorders

    40 shares
    Share 16 Tweet 10
  • New findings help explain how COVID-19 overpowers the immune system

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

GeneticsPublic HealthCell BiologyBiologyClimate ChangeMaterialsEcology/EnvironmentInfectious/Emerging DiseasesTechnology/Engineering/Computer SciencecancerChemistry/Physics/Materials SciencesMedicine/Health

Recent Posts

  • Late rainy season reliably predicts drought in regions prone to food insecurity
  • Internet and freedom of speech, when metaphors give too much power
  • Cancer can be precisely diagnosed using a urine test with artificial intelligence
  • Antibiotic resistance may spread even more easily than expected
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In